Transmitted Fetal Immune Response in Cases of SARS-CoV-2 Infections during Pregnancy
Abstract
:1. Introduction
2. Materials and Methods
2.1. Ethical Aspects
2.2. Procedures
2.3. Analysis
3. Results
Placental Study
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Liu, H.; Wang, L.L.; Zhao, S.J.; Kwak-Kim, J.; Mor, G.; Liao, A.H. Why are pregnant women susceptible to COVID-19? An immunological viewpoint. J. Reprod. Immunol. 2020, 139, 103122. [Google Scholar] [CrossRef] [PubMed]
- de Souza Silva, G.A.; da Silva, S.P.; da Costa, M.A.S.; da Silva, A.R.; de Vasconcelos Alves, R.R.; das Chagas Ângelo Mendes Tenório, F.; da Silva Melo, A.R.; de Freitas, A.C.; de Melo, C.M.L. SARS-CoV, MERS-CoV and SARS-CoV-2 infections in pregnancy and fetal development. J. Gynecol. Obstet. Human Reprod. 2020, 49, 101846. [Google Scholar] [CrossRef] [PubMed]
- Wong, S.F.; Chow, K.M.; Leung, T.N.; Ng, W.F.; Ng, T.K.; Shek, C.C.; Ng, P.C.; Lam, P.W.Y.; Ho, L.C.; To, W.W.K.; et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am. J. Obstet. Gynecol. 2004, 191, 292–297. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pollán, M.; Pérez-Gómez, B.; Pastor-Barriuso, R.; Oteo, J.; Hernán, M.A.; Pérez-Olmeda, M.; Sanmartín, J.L.; Fernández-García, A.; Cruz, I.; Fernández de Larrea, N.; et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): A nationwide, population-based seroepidemiological study. Lancet 2020, 396, 535–544. [Google Scholar] [CrossRef]
- Juan, J.; Gil, M.M.; Rong, Z.; Zhang, Y.; Yang, H.; Poon, L.C. Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: Systematic review. Ultrasound Obstet. Gynecol. 2020, 56, 15–27. [Google Scholar] [CrossRef] [PubMed]
- Mirbeyk, M.; Saghazadeh, A.; Rezaei, N. A systematic review of pregnant women with COVID-19 and their neonates. Arch. Gynecol. Obstet. 2021, 304, 5–38. [Google Scholar] [CrossRef]
- Galang, R.R.; Newton, S.M.; Woodworth, K.R.; Griffin, I.; Oduyebo, T.; Sancken, C.L.; Olsen, E.O.M.; Aveni, K.; Wingate, H.; Shephard, H.; et al. Risk Factors for Illness Severity Among Pregnant Women with Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 Infection-Surveillance for Emerging Threats to Mothers and Babies Network, 22 State, Local, and Territorial Health Departments, 29 March 2020–5 March 2021. Clin. Infect. Dis. 2021, 73, S17–S23. [Google Scholar] [CrossRef]
- Allotey, J.; Stallings, E.; Bonet, M.; Yap, M.; Chatterjee, S.; Kew, T.; Debenham, L.; Llavall, A.C.; Dixit, A.; Zhou, D.; et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: Living systematic review and meta-analysis. BMJ 2020, 370, 3320. [Google Scholar] [CrossRef]
- Mullins, E.; Hudak, M.L.; Banerjee, J.; Getzlaff, T.; Townson, J.; Barnette, K.; Playle, R.; Perry, A.; Bourne, T.; Lees, C.C.; et al. Pregnancy and neonatal outcomes of COVID-19: Coreporting of common outcomes from PAN-COVID and AAP-SONPM registries. Ultrasound Obstet. Gynecol. 2021, 57, 573–581. [Google Scholar] [CrossRef] [PubMed]
- Moltner, S.; de Vrijer, B.; Banner, H. Placental infarction and intrauterine growth restriction following SARS-CoV-2 infection. Arch. Gynecol. Obstet. 2021, 304, 1. [Google Scholar] [CrossRef]
- Linehan, L.; O’Donoghue, K.; Dineen, S.; White, J.; Higgins, J.R.; Fitzgerald, B. SARS-CoV-2 placentitis: An uncommon complication of maternal COVID-19. Placenta 2021, 104, 261–266. [Google Scholar] [CrossRef] [PubMed]
- Watkins, J.C.; Torous, V.F.; Roberts, D.J. Defining severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) placentitis a report of 7 cases with confirmatory in situ hybridization, distinct histomorphologic features, and evidence of complement deposition. Arch. Pathol. Lab. Med. 2021, 145, 1341–1349. [Google Scholar] [CrossRef]
- Schwartz, D.A.; Baldewijns, M.; Benachi, A.; Bugatti, M.; Collins, R.R.J.; de Luca, D.; Facchetti, F.; Linn, R.L.; Marcelis, L.; Morotti, D.; et al. Chronic histiocytic intervillositis with trophoblast necrosis is a risk factor associated with placental infection from coronavirus disease 2019 (COVID-19) and intrauterine maternal-fetal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in live-born and stillborn infants. Arch. Pathol. Lab. Med. 2021, 145, 517–528. [Google Scholar] [CrossRef]
- Torous, V.F.; Watkins, J.C.; Roberts, D.J. Response to “Diffuse trophoblast damage is the hallmark of SARS-CoV-2-associated fetal demise”. Mod. Pathol. 2021, 1, 2. [Google Scholar] [CrossRef]
- Mendoza, M.; Garcia-Ruiz, I.; Maiz, N.; Rodo, C.; Garcia-Manau, P.; Serrano, B.; Lopez-Martinez, R.M.; Balcells, J.; Fernandez-Hidalgo, N.; Carreras, E.; et al. Pre-eclampsia-like syndrome induced by severe COVID-19: A prospective observational study. BJOG Int. J. Obstet. Gynaecol. 2020, 127, 1374–1380. [Google Scholar] [CrossRef] [PubMed]
- Papageorghiou, A.T.; Deruelle, P.; Gunier, R.B.; Rauch, S.; García-May, P.K.; Mhatre, M.; Usman, M.A.; Abd-Elsalam, S.; Etuk, S.; Simmons, L.E.; et al. Preeclampsia and COVID-19: Results from the INTERCOVID prospective longitudinal study. Am. J. Obstet. Gynecol. 2021, 225, 289.e1. [Google Scholar] [CrossRef]
- Chen, R.; Zhang, S.; Su, S.; Ye, H.; Shu, H. Interactions between Specific Immune Status of Pregnant Women and SARS-CoV-2 Infection. Front. Cell. Infect. Microbiol. 2021, 11, 721309. [Google Scholar] [CrossRef] [PubMed]
- Mor, G.; Aldo, P.; Alvero, A.B. The unique immunological and microbial aspects of pregnancy. Nat. Rev. Immunol. 2017, 17, 469–482. [Google Scholar] [CrossRef]
- Olmos-Ortiz, A.; Flores-Espinosa, P.; Mancilla-Herrera, I.; Vega-Sánchez, R.; Díaz, L.; Zaga-Clavellina, V. Innate immune cells and toll-like receptor–dependent responses at the maternal–fetal interface. Int. J. Mol. Sci. 2019, 20, 3654. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Taglauer, E.; Benarroch, Y.; Rop, K.; Barnett, E.; Sabharwal, V.; Yarrington, C.; Wachman, E.M. Consistent localization of SARS-CoV-2 spike glycoprotein and ACE2 over TMPRSS2 predominance in placental villi of 15 COVID-19 positive maternal-fetal dyads. Placenta 2020, 100, 69–74. [Google Scholar] [CrossRef]
- Fahmi, A.; Brügger, M.; Démoulins, T.; Zumkehr, B.; Oliveira Esteves, B.I.; Bracher, L.; Wotzkow, C.; Blank, F.; Thiel, V.; Baud, D.; et al. SARS-CoV-2 can infect and propagate in human placenta explants. Cell Rep. Med. 2021, 2, 100456. [Google Scholar] [CrossRef]
- Diriba, K.; Awulachew, E.; Getu, E. The effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternal-fetal transmission: A systematic review and meta-analysis. Eur. J. Med. Res. 2020, 25, 39. [Google Scholar] [CrossRef] [PubMed]
- Rosen, H.; Bart, Y.; Zlatkin, R.; Ben-Sira, L.; Ben Bashat, D.; Amit, S.; Cohen, C.; Regev-Yochay, G.; Yinon, Y. Fetal and Perinatal Outcome Following First and Second Trimester COVID-19 Infection: Evidence from a Prospective Cohort Study. J. Clin. Med. 2021, 10, 2152. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Zhao, R.; Zheng, S.; Chen, X.; Wang, J.; Sheng, X.; Zhou, J.; Cai, H.; Fang, Q.; Yu, F.; et al. Lack of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China. Emerg. Infect. Dis. 2020, 26, 1335–1336. [Google Scholar] [CrossRef]
- Wang, S.; Guo, L.; Chen, L.; Liu, W.; Cao, Y.; Zhang, J.; Feng, L. A Case Report of Neonatal 2019 Coronavirus Disease in China. Clin. Infect. Dis. 2020, 71, 853–857. [Google Scholar] [CrossRef]
- Zeng, H.; Xu, C.; Fan, J.; Tang, Y.; Deng, Q.; Zhang, W.; Long, X. Antibodies in Infants Born to Mothers with COVID-19 Pneumonia. J. Am. Med. Assoc. 2020, 323, 1848–1849. [Google Scholar] [CrossRef]
- BioNova; Diaclone Immunology Products Quick Guide Catalogue Version 6. 2020, pp. 1–24. Available online: https://www.bionova.es/documents/diaclone/diaclone_catalog_2019.pdf (accessed on 20 December 2021).
- Biosystems Switzerland AG. BOND RNAscope Detection Reagents—Brown. Available online: https://www.biosystems.ch/default.aspx?globalid=4103598&lang=EN (accessed on 1 January 2022).
- Ashary, N.; Bhide, A.; Chakraborty, P.; Colaco, S.; Mishra, A.; Chhabria, K.; Jolly, M.K.; Modi, D. Single-Cell RNA-seq Identifies Cell Subsets in Human Placenta That Highly Expresses Factors Driving Pathogenesis of SARS-CoV-2. Front. Cell Dev. Biol. 2020, 8. [Google Scholar] [CrossRef]
- Zheng, Q.L.; Duan, T.; Jin, L.P. Single-cell RNA expression profiling of ACE2 and AXL in the human maternal–Fetal interface. Reprod. Dev. Med. 2020, 4, 7. [Google Scholar] [CrossRef]
- Pique-Regi, R.; Romero, R.; Tarca, A.L.; Luca, F.; Xu, Y.; Alazizi, A.; Leng, Y.; Hsu, C.D.; Gomez-Lopez, N. Does the human placenta express the canonical cell entry mediators for SARS-CoV-2? Elife 2020, 9, 1–15. [Google Scholar] [CrossRef]
- Wong, Y.P.; Khong, T.Y.; Tan, G.C. The Effects of COVID-19 on Placenta and Pregnancy: What Do We Know So Far? Diagnostics 2021, 11, 94. [Google Scholar] [CrossRef] [PubMed]
- Waysbort, A.; Giroux, M.; Mansat, V.; Teixeira, M.; Dumas, J.C.; Puel, J. Experimental study of transplacental passage of alpha interferon by two assay techniques. Antimicrob. Agents Chemother. 1993, 37, 1232–1237. [Google Scholar] [CrossRef] [Green Version]
- Yockey, L.J.; Iwasaki, A. Interferons and Proinflammatory Cytokines in Pregnancy and Fetal Development. Immunity 2018, 49, 397–412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Flannery, D.D.; Gouma, S.; Dhudasia, M.B.; Mukhopadhyay, S.; Pfeifer, M.R.; Woodford, E.C.; Triebwasser, J.E.; Gerber, J.S.; Morris, J.S.; Weirick, M.E.; et al. Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios. JAMA Pediatr. 2021, 175, 594–600. [Google Scholar] [CrossRef] [PubMed]
- Joseph, N.T.; Dunlop, A.L.; Patel, R.M.; Badell, M.; Dude, C. LB01 Maternal antibody response and placental antibody transfer following asymptomatic and symptomatic SARS-CoV-2 infection. Am. J. Obstet. Gynecol. 2021, 224, S722. [Google Scholar] [CrossRef]
Minimum Detectable Dose | Intra-Assay Variation Coefficient | Inter-Assay Variation Coefficient | Tested Absence of Cross-Reactivity | |
---|---|---|---|---|
RayBio® Human IL-1 beta ELISA Kit (RayBio® ref. ELH-IL1b) | 0.3 pg/mL | <10% | <12% | IL-1α. IL-1β. IL-2. IL-4. IL-8. IL-10. IL-12. IL-13. IFNγ and TNFα |
Human IL-6 High Sensitivity ELISA Kit (Diaclone. ref. 950.035.096) | 0.81 pg/mL | 4.4% | 9.1% | IL-1α, IL-1β, IL-2, IL-4, IL-8, IL-10, IL-12, IL-12, IFNγ y TNFα |
Human IFNγ High Sensitivity ELISA Kit (Diaclone. ref. 850.900.096) | 0.69 pg/ml | 3.9% | 8.6% | IL-1α. IL-2. IL-8. IL-12p40. TNFα. CD95/Fas. TRAIL. ICAM-1. gp130 and GM-CSF |
Human SARS-CoV-2 Spike Protein S1 IgM (MyBioSource. ref. MBS2614311) | 1.2 U/mL | 8% | 12% | IgM analogues |
COVID-19 (SARS-CoV-2) quantitative IgG ELISA (Demeditec. ref. DECOV1901Q) | 3.6 AU/mL | 5.3% | 9.9% | IgG analogues |
Hb | WBC | Platelets | Neutrophils | Lymphocytes | Monocytes | Eosinophils | Basophils | Granulocytes Immature (%) | ||
---|---|---|---|---|---|---|---|---|---|---|
Mean | 11.60 | 10.67 | 231.08 | 8.06 | 1.83 | 0.67 | 0.06 | 0.03 | 0.79 | |
Std. Deviation | 1.250 | 3.44 | 67.96 | 3.28 | 0.57 | 0.24 | 0.08 | 0.01 | 0.83 | |
Minimum | 7.90 | 4.79 | 99.00 | 3.18 | 0.77 | 0.33 | 0.00 | 0.01 | 0.03 | |
Maximum | 14.00 | 20.66 | 408.00 | 18.77 | 3.79 | 1.71 | 0.50 | 0.09 | 6.00 | |
Percentiles | 25 | 10.87 | 8.08 | 182.00 | 5.68 | 1.43 | 0.50 | 0.02 | 0.02 | 0.4 |
50 | 11.60 | 9.79 | 234.00 | 7.06 | 1.84 | 0.62 | 0.03 | 0.03 | 0.60 | |
75 | 12.42 | 12.54 | 268.75 | 9.76 | 2.19 | 0.76 | 0.08 | 0.04 | 0.95 |
Hb | WBC | Plate- Lets | Neutrophils | Lymphocytes | Monocytes | Eosinophils | Basophils | Granulocyte Immature (%) | Erythroblasts | |
---|---|---|---|---|---|---|---|---|---|---|
Mean | 15.91 | 14.58 | 305.23 | 7.89 | 4.96 | 1.50 | 0.50 | 0.14 | 3.40 | 0.88 |
Std. Deviation | 1.67 | 4.04 | 70.55 | 3.06 | 2.46 | 0.71 | 0.38 | 0.20 | 2.44 | 1.45 |
Minimum | 12.80 | 8.20 | 34.00 | 2.56 | 2.78 | 0.69 | 0.00 | 0.01 | 0.08 | 0.00 |
Maximum | 22.80 | 25.55 | 470.00 | 18.00 | 20.30 | 5.30 | 2.50 | 1.50 | 9.60 | 9.10 |
25th Percentile | 14.77 | 11.38 | 269.00 | 5.83 | 3.80 | 1.05 | 0.28 | 0.06 | 1.10 | 0.20 |
50th Percentile | 15.75 | 14.24 | 300.00 | 7.14 | 4.36 | 1.41 | 0.42 | 0.10 | 3.00 | 0.40 |
75th Percentile | 16.80 | 18.11 | 347.00 | 8.94 | 5.69 | 1.75 | 0.61 | .014 | 5.00 | 0.90 |
Ab IgM (U/mL) | Ab IgG (U/mL) | IL-6 (pg/mL) | IL1B (pg/mL) | IFN-γ (pg/mL) | ||
---|---|---|---|---|---|---|
Mean | 0.17 | 4227.91 | 11.53 | 0.58 | 7.02 | |
Std. Deviation | 0.36 | 5817.53 | 20.46 | 0.32 | 4.97 | |
Minimum | 0.00 | 108.2 | 2.1 | 0.3 | 0.7 | |
Maximum | 1.55 | 28348.6 | 109.1 | 1.9 | 18.8 | |
Percentiles | 25 | 0.00 | 246.81 | 3.18 | 0.43 | 1.56 |
50 | 0.00 | 1798.70 | 4.21 | 0.47 | 6.85 | |
75 | 0.15 | 5871.07 | 7.29 | 0.55 | 10.64 |
Time of Evolution | Ab IgG (U/mL) | IL-6 (pg/mL) | IL1B (pg/mL) | IFN-γ (pg/mL) | |
---|---|---|---|---|---|
Ab IgG (U/mL) | 0.301 ** | 1 | |||
IL-6 (pg/mL) | 0.053 | 0.002 | 1 | ||
IL1B (pg/mL) | −0.138 | 0.030 | 0.397 ** | 1 | |
IFNg (pg/mL) | 0.280 ** | 0.064 | −0.013 | −0.083 | 1 |
Hb | WBC | Platelets | Neutrophils | Lymphocytes | Monocytes | Eosinophils | Basophiles | Granulocytes Immature | |
---|---|---|---|---|---|---|---|---|---|
Ab IgG (U/mL) | −0.17 | 0.094 | 0.052 | 0.121 | −0.130 | 0.014 | −0.039 | −0.011 | −0.056 |
IL-6 (pg/mL) | −0.08 | 0.037 | −0.084 | 0.055 | −0.090 | −0.001 | −0.037 | 0.109 | 0.071 |
IL1B (pg/mL) | 0.00 | 0.017 | 0.051 | −0.002 | 0.095 | 0.027 | 0.336 * | 0.046 | −0.022 |
IFN-γ (pg/mL) | 0.14 | 0.080 | 0.072 | 0.121 | −0.170 | −0.057 | −0.155 | 0.167 | 0.127 |
Hb | WBC | Platelets | Neutrophils | Lymphocytes | Monocytes | Eosinophils | Basophils | Granulocytes Immature (%) | Erythroblasts | |
---|---|---|---|---|---|---|---|---|---|---|
Ab IgG (U/mL) | 0.002 | −0.014 | 0.078 | 0.093 | 0.001 | 0.011 | −0.168 | 0.013 | 0.028 | 0.126 |
IL-6 (pg/mL) | −0.111 | −0.085 | 0.155 | 0.167 | 0.006 | 0.094 | −0.103 | −0.027 | 0.146 | −0.111 |
IL1B (pg/mL) | −0.005 | −0.058 | 0.009 | 0.002 | −0.181 | −0.125 | −0.144 | −0.205 | −0.066 | 0.111 |
IFN-γ (pg/mL) | 0.111 | 0.020 | 0.261 * | 0.308 | −0.106 | 0.070 | 0.169 | −0.012 | 0.332 *^ | −0.029 |
Neutrophils | Lymphocytes | |
---|---|---|
IgG | ||
<75th Percentile | 7.88 (3.1) | 4.96 (2.6) |
>75th Percentile | 7.94 (2.93) | 4.95 (1.6) |
Interferon | - | |
<75th Percentile | 7.68 (2.76) | - |
>75th Percentile | 8.82 (4.18) | - |
Subsets | Mean | Median | Std Dev | p 25 | p 50 | p 75 |
---|---|---|---|---|---|---|
% CD3+ | 42.52 | 40.15 | 12.948 | 31.55 | 40.15 | 53.675 |
% CD3+INKT+ | 1.695 | 1 | 1.7929 | 0.3 | 1 | 2.6 |
% CD3+INKT+CD34+ | 88.573 | 89.05 | 6.779 | 84.675 | 89.05 | 92.1 |
% CD3+CD4+ | 30.69 | 30.7 | 11.154 | 19.025 | 30.7 | 39.875 |
% CD3+CD4+CD34+ | 65.115 | 64.55 | 10.842 | 54.825 | 64.55 | 75.925 |
CD3+CD8+ | 11.708 | 11.1 | 4.497 | 8.225 | 11.1 | 14.375 |
% CD3+CD8+CD34+ | 35.132 | 32.25 | 14.446 | 23.8 | 32.25 | 45.7 |
Ratio CD4+/CD8+ | 2.874 | 2.67 | 1.198 | 2.199 | 2.674 | 3.555 |
Ratio CD4+CD34+/CD8+CD34+ | 2.089 | 2.006 | 0.667 | 1.59 | 2.00 | 2.44 |
CD3+ | CD3+ INKT+ | CD3+INKT+ CD34+ | CD3+ CD4+ | CD3+CD4+ CD34+ | CD3+ CD8+ | CD3+CD8+ CD34+ | |
---|---|---|---|---|---|---|---|
Hb | 0.140 | 0.044 | 0.014 | 0.165 | 0.065 | 0.012 | −0.021 |
WBC | −0.310 | 0.120 | 0.069 | −0.426 | 0.036 | 0.132 | 0.080 |
Platelets | −0.362 | 0.135 | −0.270 | −0.275 | −0.237 | −0.310 | 0.030 |
Neutrophils | −0.329 | 0.094 | 0.118 | −0.452 * | 0.031 | 0.143 | 0.070 |
Lymphocytes | −0.009 | 0.076 | −0.255 | 0.010 | −0.108 | −0.066 | −0.033 |
Monocytes | −0.088 | 0.257 | 0.088 | −0.144 | 0.290 | 0.078 | 0.229 |
Eosinophils | −0.034 | 0.089 | −0.138 | −0.070 | 0.184 | 0.075 | 0.237 |
Basophils | −0.169 | 0.013 | −0.386 | −0.211 | −0.168 | 0.041 | −0.067 |
Granulocytes | −0.189 | −0.253 | −0.385 | −0.176 | −0.352 * | −0.094 | −0.296 |
CD3+ | CD3+ INKT+ | CD3+INKT+ CD34+ | CD3+ CD4+ | CD3+CD4+ CD34+ | CD3+ CD8+ | CD3+CD8+ CD34+ | |
---|---|---|---|---|---|---|---|
Hb | 0.048 | −0.069 | 0.299 | 0.096 | 0.199 | −0.122 | 0.088 |
WBC | −0.117 | 0.033 | −0.068 | −0.158 | −0.131 | 0.038 | −0.004 |
Platelets | −0.268 | 0.335 | −0.101 | −0.199 | 0.126 | −0.281 | 0.107 |
Neutrophils | −0.247 | 0.445 * | −0.214 | −0.186 | 0.084 | −0.229 | 0.201 |
Lymphocytes | −0.251 | 0.581 ** | −0.238 | −0.188 | 0.246 | −0.238 | 0.287 |
Monocytes | −0.237 | 0.568 ** | −0.225 | −0.178 | 0.219 | −0.221 | 0.303 |
Eosinophils | −0.108 | 0.437 * | −0.059 | −0.085 | 0.322 | −0.086 | 0.307 |
Basophils | −0.289 | 0.607 ** | −0.266 | −0.238 | 0.150 | −0.211 | 0.311 |
Granulocytes | −0.315 | 0.272 | 0.123 | −0.280 | 0.178 | −0.239 | 0.152 |
Erythroblasts | −0.381 * | 0.210 | −0.025 | −0.301 | −0.171 | −0.338 | −0.039 |
CD3+ | CD3+ INKT+ | CD3+INKT+ CD34+ | CD3+ CD4+ | CD3+CD4+ CD34+ | CD3+ CD8+ | CD3+CD8+ CD34+ | |
---|---|---|---|---|---|---|---|
Ab IgG (U/mL) | 0.434 ** | 0.079 | 0.069 | 0.316 * | 0.217 | 0.481 ** | 0.156 |
IL-6 (pg/mL) | −0.047 | −0.062 | −0.028 | −0.074 | −0.128 | 0.047 | −0.139 |
IL1B (pg/mL) | −0.264 | 0.460 ** | −0.186 | −0.218 | 0.105 | −0.213 | 0.333 * |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
González-Mesa, E.; García-Fuentes, E.; Carvia-Pontiasec, R.; Lavado-Fernández, A.I.; Cuenca-Marín, C.; Suárez-Arana, M.; Blasco-Alonso, M.; Benítez-Lara, B.; Mozas-Benítez, L.; González-Cazorla, A.; et al. Transmitted Fetal Immune Response in Cases of SARS-CoV-2 Infections during Pregnancy. Diagnostics 2022, 12, 245. https://doi.org/10.3390/diagnostics12020245
González-Mesa E, García-Fuentes E, Carvia-Pontiasec R, Lavado-Fernández AI, Cuenca-Marín C, Suárez-Arana M, Blasco-Alonso M, Benítez-Lara B, Mozas-Benítez L, González-Cazorla A, et al. Transmitted Fetal Immune Response in Cases of SARS-CoV-2 Infections during Pregnancy. Diagnostics. 2022; 12(2):245. https://doi.org/10.3390/diagnostics12020245
Chicago/Turabian StyleGonzález-Mesa, Ernesto, Eduardo García-Fuentes, Rafael Carvia-Pontiasec, Ana I. Lavado-Fernández, Celia Cuenca-Marín, María Suárez-Arana, Marta Blasco-Alonso, Blanca Benítez-Lara, Laura Mozas-Benítez, Ana González-Cazorla, and et al. 2022. "Transmitted Fetal Immune Response in Cases of SARS-CoV-2 Infections during Pregnancy" Diagnostics 12, no. 2: 245. https://doi.org/10.3390/diagnostics12020245
APA StyleGonzález-Mesa, E., García-Fuentes, E., Carvia-Pontiasec, R., Lavado-Fernández, A. I., Cuenca-Marín, C., Suárez-Arana, M., Blasco-Alonso, M., Benítez-Lara, B., Mozas-Benítez, L., González-Cazorla, A., Egeberg-Neverdal, H., & Jiménez-López, J. S. (2022). Transmitted Fetal Immune Response in Cases of SARS-CoV-2 Infections during Pregnancy. Diagnostics, 12(2), 245. https://doi.org/10.3390/diagnostics12020245